---
layout: entry
title: "No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy"
link: "https://doi.org/10.1111/jdv.16552"
author:
- Carugno, A.; Raponi, F.; Locatelli, A. G.; Vezzoli, P.; Gambini, D. M.; Di Mercurio, M.; Robustelli Test, E.; Sena, P.

summary:
- "Atopic dermatitis (AD) is a chronic inflammatory skin disease. Patients with AD have increased infection risk, including skin infections and systemic infections. Dupilumab blocks the shared receptor component for interleukin-4 (IL-4) and IL-13. The antibody is approved for inadequately controlled moderate-to-severe AD.1. Symptoms include skin infections, systemic infection."

original:
- "Atopic dermatitis (AD) is a chronic inflammatory skin disease. Patients with AD have increased infection risk, including skin infections and systemic infections. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 (IL-4) and IL-13. Dupilumab is approved for inadequately controlled moderate-to-severe AD.1"
---

